Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
FDA Oncology Update
,
CAR T-Cell Therapy
,
Multiple Myeloma
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
Read More
Multiple Myeloma
Phase 1/2 Study Results of BCMA x CD3 Bispecific Monoclonal Antibody REGN5458 in Patients with RRMM
Read More
Multiple Myeloma
Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM
Read More
Multiple Myeloma
Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance
Read More
Multiple Myeloma
First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma
Read More
Multiple Myeloma
End-of-Study Analysis of the LYRA Study of Daratumumab Maintenance Therapy Following DARA plus CyBorD Induction Therapy in MM
Read More
Multiple Myeloma
MagnetisMM-1 Trial Results of Elranatamab in Patients with RRMM
Read More
Multiple Myeloma
Isatuximab Short-Duration, Fixed-Volume Infusion plus VRd for Patients with NDMM Ineligible or with No Intent for Immediate ASCT
Read More
Multiple Myeloma
Daratumumab plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard-Risk Transplant-Eligible NDMM
Read More
Multiple Myeloma
Results of the Phase 2 HOVON 143 Study of Induction Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Intermediate-Fit Patients with NDMM
Read More
1
2
3
4
5
6
Page 3 of 10
Results 21 - 30 of 98